Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a secondgeneration integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV.
CITATION STYLE
Wainberg, M. A., Han, Y. S., & Mesplède, T. (2016). Might dolutegravir be part of a functional cure for HIV? Canadian Journal of Microbiology. Canadian Science Publishing. https://doi.org/10.1139/cjm-2015-0725
Mendeley helps you to discover research relevant for your work.